We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
+3.64%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$62.8M
AUM Growth
-$8.16M
(-11%)
Cap. Flow
-$11.1M
Cap. Flow
% of AUM
-17.63%
Top 10 Holdings %
Top 10 Hldgs %
97.34%
Holding
18
New
5
Increased
1
Reduced
6
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$6.26M |
| 2 |
Biogen
BIIB
|
+$6.09M |
| 3 |
Cigna
CI
|
+$5.62M |
| 4 |
Zevra Therapeutics
ZVRA
|
+$1.62M |
| 5 |
Utah Medical Products
UTMD
|
+$1.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$6.5M |
| 2 |
Cencora
COR
|
+$6.38M |
| 3 |
LCI
Lannett Company, Inc.
LCI
|
+$3.24M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$3.17M |
| 5 |
Harmony Biosciences
HRMY
|
+$3.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
McKesson
MCK
$103B
| $9.18M | 14.62% |
30,000
-4,000
| -12% | -$1.09M |
|
2
Ironwood Pharmaceuticals
IRWD
$705M
| $8.93M | 14.22% |
710,000
-20,000
| -3% | -$229K |
|
3
Bristol-Myers Squibb
BMY
$131B
| $5.99M | 9.53% |
82,000
-18,000
| -18% | -$1.21M |
|
|
4
Biogen
BIIB
$30.4B
| $5.9M | 9.39% |
+28,000
| New | +$6.09M |
|
|
5
Harmony Biosciences
HRMY
$2.27B
| $5.84M | 9.3% |
120,000
-75,000
| -38% | -$3.06M |
|
|
6
Gilead Sciences
GILD
$165B
| $5.83M | 9.28% |
+98,000
| New | +$6.26M |
|
|
7
Cigna
CI
$74.3B
| $5.75M | 9.16% |
+24,000
| New | +$5.62M |
|
8
Cardinal Health
CAH
$56.1B
| $5.67M | 9.03% |
100,000
-25,000
| -20% | -$1.34M |
|
|
9
Utah Medical Products
UTMD
$221M
| $5.03M | 8.01% |
56,000
+16,000
| +40% | +$1.47M |
|
|
LJPC
10
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $3.02M | 4.81% |
707,000
-123,000
| -15% | -$536K |
|
|
11
Zevra Therapeutics
ZVRA
$695M
| $1.28M | 2.04% |
+255,000
| New | +$1.62M |
|
|
OPNT
12
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
| $386K | 0.61% |
+18,000
| New | +$477K |
|
|
13
AbbVie
ABBV
$432B
| – | – |
-48,000
| Closed | -$6.5M |
|
|
14
Cencora
COR
$62.2B
| – | – |
-48,000
| Closed | -$6.38M |
|
15
Rigel Pharmaceuticals
RIGL
$757M
| – | – |
-109,000
| Closed | -$2.89M |
|
|
ICPT
16
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-183,000
| Closed | -$2.98M |
|
|
LCI
17
DELISTED
Lannett Company, Inc.
LCI
| – | – |
-500,000
| Closed | -$3.24M |
|
|
ZGNX
18
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-195,000
| Closed | -$3.17M |
|
Similar funds
KP
TCM
SAAM
PAA
PC
BOCH
GIP
PC
HealthInvest Partners's Q1 2022 Portfolio in Review
As of Q1 2022, HealthInvest Partners held 18 positions worth $62.8M, down 11% from $71M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
HealthInvest Partners withdrew a net $11.1M in Q1 2022, closing 6 positions and reducing 6 holdings. Its most notable exit was AbbVie, an estimated $6.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, HealthInvest Partners opened a new position in Gilead Sciences worth $5.83M.
- HealthInvest Partners's largest Q1 2022 buy was Gilead Sciences: 98,000 shares worth $5.83M.
- HealthInvest Partners added most to Utah Medical Products in Q1 2022, an estimated $1.47M increase.
- HealthInvest Partners's biggest Q1 2022 reduction was Harmony Biosciences, cutting an estimated $3.06M.
- HealthInvest Partners fully exited AbbVie in Q1 2022, selling an estimated $6.5M.
- HealthInvest Partners's ten largest holdings make up 97% of its $62.8M portfolio in Q1 2022.
- HealthInvest Partners opened 5 new positions and closed 6 in Q1 2022.
- HealthInvest Partners's portfolio value fell 11% quarter-over-quarter to $62.8M.
Based on HealthInvest Partners's 13F filing for Q1 2022, filed 5 May 2022.